Ken Griffin Co Diagnostics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Co Diagnostics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 9,100 shares of CODX stock, worth $6,643. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,100

Previous 3,300 175.76%

Holding current value

$6,643

Previous $4,000 175.0%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.02 - $1.75 $28,920 - $49,617	-28,353 Reduced 52.72%	25,423 $31,000
Q2 2024 Aug 14, 2024	SELL	$1.01 - $1.7 $19,346 - $32,563	-19,155 Reduced 26.26%	53,776 $67,000
Q1 2024 May 15, 2024	SELL	$1.06 - $1.42 $25,138 - $33,676	-23,716 Reduced 24.54%	72,931 $81,000
Q4 2023 Feb 14, 2024	BUY	$1.0 - $1.5 $24,372 - $36,558	24,372 Added 33.72%	96,647 $128,000
Q3 2023 Nov 14, 2023	BUY	$1.03 - $1.85 $17,294 - $31,063	16,791 Added 30.26%	72,275 $76,000
Q2 2023 Aug 14, 2023	BUY	$1.04 - $1.64 $23,192 - $36,572	22,300 Added 67.2%	55,484 $61,000
Q1 2023 May 15, 2023	BUY	$1.39 - $3.24 $14,387 - $33,537	10,351 Added 45.33%	33,184 $49,000
Q4 2022 Feb 14, 2023	BUY	$2.32 - $3.68 $52,972 - $84,025	22,833 New	22,833 $57,000
Q2 2022 Aug 15, 2022	BUY	$3.76 - $6.29 $148,790 - $248,907	39,572 Added 47.62%	122,673 $688,000
Q1 2022 May 16, 2022	BUY	$5.03 - $9.61 $41,517 - $79,320	8,254 Added 11.03%	83,101 $514,000
Q4 2021 Feb 14, 2022	SELL	$8.12 - $10.37 $372,837 - $476,148	-45,916 Reduced 38.02%	74,847 $668,000
Q3 2021 Nov 15, 2021	SELL	$7.48 - $11.38 $781,113 - $1.19 Million	-104,427 Reduced 46.37%	120,763 $1.18 Million
Q2 2021 Aug 16, 2021	BUY	$7.16 - $9.56 $782,702 - $1.05 Million	109,316 Added 94.34%	225,190 $1.86 Million
Q1 2021 May 17, 2021	BUY	$8.52 - $19.21 $723,952 - $1.63 Million	84,971 Added 274.96%	115,874 $1.11 Million
Q4 2020 Feb 16, 2021	SELL	$9.3 - $15.19 $174,207 - $284,539	-18,732 Reduced 37.74%	30,903 $287,000
Q3 2020 Nov 16, 2020	SELL	$8.24 - $30.8 $1.89 Million - $7.07 Million	-229,601 Reduced 82.22%	49,635 $675,000
Q2 2020 Aug 14, 2020	BUY	$7.46 - $23.42 $1.33 Million - $4.16 Million	177,777 Added 175.22%	279,236 $5.4 Million
Q1 2020 May 15, 2020	BUY	$0.91 - $17.81 $92,327 - $1.81 Million	101,459 New	101,459 $773,000
Q4 2019 Feb 14, 2020	SELL	$0.88 - $1.12 $17,951 - $22,846	-20,399 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$0.81 - $1.35 $2,337 - $3,896	-2,886 Reduced 12.39%	20,399 $21,000
Q4 2018 Feb 14, 2019	BUY	$1.15 - $2.61 $10,981 - $24,922	9,549 Added 69.52%	23,285 $34,000
Q3 2018 Nov 13, 2018	SELL	$2.63 - $4.24 $3,255 - $5,249	-1,238 Reduced 8.27%	13,736 $0
Q1 2018 May 11, 2018	BUY	$1.56 - $3.2 $23,359 - $47,916	14,974 New	14,974 $33,000

Others Institutions Holding CODX

# of Institutions

Shares Held

4.28M

Call Options Held

48.2K

Put Options Held

53.3K

View Full List

About Co-Diagnostics, Inc.

Ticker CODX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 33,781,000
Market Cap $24.7M
Description
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and ...

More about CODX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account